Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of xanomeline + trospium for cognitive impairment in adults with schizophrenia
NL-OMON60931Phase 3Withdrawn
- Sponsor
- European Group for Research in Schizophrenia
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of xanomeline and trospium in schizophrenia, sponsored by European Group for Research in Schizophrenia. Primary endpoint: Change from baseline to week 24 in the BACS composite cognitive score. Planned start Jan 2026; status: withdrawn.
02
Drugs
xanomelinetrospium
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON60931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60931.